Evidence map›Paper›PMID 32104682›Full record

ArticleBioMed research international2020

Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells.

Yuanshen Mao, Wenfeng Li, Bao Hua, Xin Gu, Weixin Pan, Qi Chen, Bin Xu, Zhong Wang, Chao Lu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Frontiers in oncology · 2021
    Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuanshen MaoDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0003-4120-415X
Wenfeng LiDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0002-5983-7716
Bao HuaDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0002-0636-7474
Xin GuDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0003-3642-2996
Weixin PanDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0001-6720-2764
Qi ChenDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0001-5971-7872
Bin XuDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0001-7998-9314
Zhong WangDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0001-9787-7332
Chao LuDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China.ORCID https://orcid.org/0000-0001-5517-3812
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ELK3, an ETS domain-containing transcription factor, participates in various physiological and pathological processes including cell proliferation, migration, angiogenesis, and malignant progression. However, the role of ELK3 in prostate cancer cells and its mechanism are not fully understood. The contribution of ELK3 to prostate cancer progression was investigated in the present study. We showed that silencing of ELK3 by siRNA in prostate cancer cell DU145 induced S-M phase arrest, promoted apoptosis, inhibited cell proliferation and migration

Indexed as

Cell MovementGene Expression Regulation, NeoplasticGene SilencingM Phase Cell Cycle CheckpointsPlasminogen Activator Inhibitor 1Prostatic NeoplasmsProto-Oncogene Proteins c-etsS Phase Cell Cycle CheckpointsUp-RegulationAnimalsCell Line, TumorHumansMaleMiceMice, Inbred BALB CMice, NudeElk3 protein, humanPlasminogen Activator Inhibitor 1Proto-Oncogene Proteins c-etsSERPINE1 protein, human

Identifiers

PMID32104682
PMCPMC7040388
OpenAlexW3006576236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.